On Friday, drug manufacturer Novo Nordisk announced it has raised its outlook for full-year operating profit and sales.
The move comes following the soaring popularity of the Danish drugmakers’ blockbuster weight loss drugs, Wegovy and Ozempic.
Novo Nordisk now predicts sales growth between 32% to 38% in 2023, up from previous estimates of 27% to 33%.
Likewise, the company expects operating profit growth in 2023 to sit between 40% to 46%, up from its prior 31% to 37% predictions.
